BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23768069)

  • 1. The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors.
    Śmigielski J; Piskorz Ł; Talar-Wojnarowska R; Malecka-Panas E; Jabłoński S; Brocki M
    World J Surg Oncol; 2013 Jun; 11():137. PubMed ID: 23768069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M; Puistola U; Turpeenniemi-Hujanen T
    Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
    Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
    Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.
    Fuksiewicz M; Kotowicz B; Rutkowski A; Kowalska M
    Tumour Biol; 2015 May; 36(5):3629-35. PubMed ID: 25549795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.
    De Cicco C; Ravasi L; Zorzino L; Sandri MT; Botteri E; Verweij F; Granchi D; de Cobelli O; Paganelli G
    Curr Cancer Drug Targets; 2008 May; 8(3):199-206. PubMed ID: 18473733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
    Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
    Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia.
    Derosa G; Maffioli P; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Mereu R; Palumbo I; Randazzo S; Cicero AF
    Clin Invest Med; 2009 Apr; 32(2):E124-32. PubMed ID: 19331801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
    Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
    J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT; Brünner N; De Muckadell OB
    Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
    Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
    Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
    Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
    Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.
    Lichtinghagen R; Huegel O; Seifert T; Haberkorn CI; Michels D; Flemming P; Bahr M; Boeker KH
    Clin Chem; 2000 Feb; 46(2):183-92. PubMed ID: 10657374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
    Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
    Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating matrix metalloproteinase MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure.
    Nissi R; Talvensaari-Mattila A; Kotila V; Niinimäki M; Järvelä I; Turpeenniemi-Hujanen T
    Reprod Biol Endocrinol; 2013 Jan; 11():2. PubMed ID: 23320481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
    Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.